CA2998739A1 - Oral pharmaceutical composition comprising cannabinoid, process for its preparation and use - Google Patents

Oral pharmaceutical composition comprising cannabinoid, process for its preparation and use Download PDF

Info

Publication number
CA2998739A1
CA2998739A1 CA2998739A CA2998739A CA2998739A1 CA 2998739 A1 CA2998739 A1 CA 2998739A1 CA 2998739 A CA2998739 A CA 2998739A CA 2998739 A CA2998739 A CA 2998739A CA 2998739 A1 CA2998739 A1 CA 2998739A1
Authority
CA
Canada
Prior art keywords
oil
composition according
cannabinoid
combinations
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2998739A
Other languages
English (en)
French (fr)
Inventor
Luiz DONADUZZI
Carmen Maria DONADUZZI
Christian Gregory Burgos DE MENEZES
Liberato Brum JUNIOR
Volnei Jose Tondo Filho
Patricia Moura ROSA
Jose Alexandre Crippa
Jaime Eduardo Cecilio HALLAK
Antonio Waldo ZUARDI
Francisco Silveira GUIMARAES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prati Donaduzzi & Cia Ltda
Universidade de Sao Paulo USP
Original Assignee
Prati Donaduzzi & Cia Ltda
Universidade de Sao Paulo USP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58288018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2998739(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Prati Donaduzzi & Cia Ltda, Universidade de Sao Paulo USP filed Critical Prati Donaduzzi & Cia Ltda
Publication of CA2998739A1 publication Critical patent/CA2998739A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CA2998739A 2015-09-18 2016-09-16 Oral pharmaceutical composition comprising cannabinoid, process for its preparation and use Abandoned CA2998739A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BR102015024165A BR102015024165A2 (pt) 2015-09-18 2015-09-18 composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
BRBR102015024165-8 2015-09-18
PCT/BR2016/050231 WO2017045053A1 (pt) 2015-09-18 2016-09-16 Composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso

Publications (1)

Publication Number Publication Date
CA2998739A1 true CA2998739A1 (en) 2017-03-23

Family

ID=58288018

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2998739A Abandoned CA2998739A1 (en) 2015-09-18 2016-09-16 Oral pharmaceutical composition comprising cannabinoid, process for its preparation and use

Country Status (8)

Country Link
US (1) US20180264121A1 (enExample)
EP (1) EP3351242A4 (enExample)
JP (1) JP2018528985A (enExample)
CN (1) CN108366988A (enExample)
AU (1) AU2016322148A1 (enExample)
BR (2) BR102015024165A2 (enExample)
CA (1) CA2998739A1 (enExample)
WO (1) WO2017045053A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021022378A1 (en) * 2019-08-08 2021-02-11 Neptune Wellness Solutions Inc. Oral formulations of cannabis extracts and methods of making same

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658137A4 (en) * 2017-07-27 2020-06-03 Shaaban, Basil Adil CANNABINOID COMPOSITION WITH OPTIMIZED FATTY ACID PROFILE
US20190083622A1 (en) * 2017-10-16 2019-03-21 Joshua Raderman Cannabinoid formulations and methods including the antioxidant c60
AU2019217673A1 (en) 2018-02-07 2020-09-24 Scf Pharma Inc. Polyunsaturated fatty acid monoglycerides, compositions, methods and uses thereof
BR102018002843A2 (pt) * 2018-02-09 2019-08-27 Prati Donaduzzi & Cia Ltda composição farmacêutica e uso da mesma
ES2992095T3 (es) 2018-05-03 2024-12-09 Scf Pharma Inc Monoglicéridos de ácidos grasos poliinsaturados, composiciones y uso de los mismos para modular la composición de la microbiota de un sujeto
US20220304963A1 (en) * 2018-07-27 2022-09-29 Basil Shaaban Composition having an optimized fatty acid excipient profile
IL261132A (en) * 2018-08-13 2018-11-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
WO2020044118A1 (en) * 2018-08-27 2020-03-05 Emerald Health Therapeutics Canada Inc. Improved cannabinoid bioavailability
CN108968071A (zh) * 2018-09-26 2018-12-11 江西中医药大学 代代花和火麻仁组合物在制备改善记忆力减退或治疗抑郁症药物或保健功能饮料中的应用
US12484606B2 (en) 2018-12-14 2025-12-02 Natural Extraction Systems, LLC Compositions and methods related to anionic cannabinoid molecules
US11026888B1 (en) 2019-01-04 2021-06-08 Nutrition Therapeutics, Inc. Functional beverage compositions and methods of using and making same
CA3040547C (en) * 2019-04-17 2021-12-07 Medcan Pharma A/S Cannabinoid lozenge formulation
US12226390B2 (en) 2019-07-21 2025-02-18 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
AU2020318671B2 (en) * 2019-07-21 2021-12-23 Scf Pharma Inc. Cannabinoids compositions with polyunsaturated fatty acid monoglycerides, methods and uses thereof
US12419855B2 (en) 2019-08-28 2025-09-23 Natural Extraction Systems, LLC Compositions comprising cannabinoid ions that are dissolved in glycerol
AU2019465548B2 (en) * 2019-09-09 2025-12-11 Cardiol Therapeutics Inc. Stable medicinal cannabidiol compositions
CN113694049B (zh) * 2020-05-21 2022-11-22 汉义生物科技（北京）有限公司 大麻素类化合物及其在治疗帕金森症中的应用
CN111603443B (zh) * 2020-06-12 2022-06-28 苏州旺山旺水生物医药有限公司 一种稳定的cbd组合物及其应用
WO2022026960A1 (en) 2020-07-31 2022-02-03 Natural Extraction Systems, LLC Compositions and methods related to excipients and cannabinoid formulations
CA3217137A1 (en) 2021-04-29 2022-11-03 Christopher Adair Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
JP2023039414A (ja) * 2021-09-08 2023-03-20 株式会社東洋新薬 経口組成物
AU2023361756A1 (en) * 2022-10-12 2025-05-22 Leiutis Pharmaceuticals Llp Novel liquid oral formulations of cannabidiol
WO2024168426A1 (en) 2023-02-13 2024-08-22 Apogee Pharmaceuticals, Inc. Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof
EP4522133A4 (en) * 2023-07-24 2025-03-19 Poviva Corp. COMPOSITIONS AND METHODS FOR THE TREATMENT OF EPILEPSY

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992004893A1 (en) * 1990-09-13 1992-04-02 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
US6703418B2 (en) * 1991-02-26 2004-03-09 Unimed Pharmaceuticals, Inc. Appetite stimulation and induction of weight gain in patients suffering from symptomatic HIV infection
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
WO2005074943A1 (ja) * 2004-02-06 2005-08-18 Chugai Seiyaku Kabushiki Kaisha Ｅｄ−７１製剤
DK1903866T3 (en) * 2005-11-07 2016-07-25 Murty Pharmaceuticals Inc Improved release of tetrahydrocannabinol
US20140357708A1 (en) * 2005-11-07 2014-12-04 Murty Pharmaceuticals, Inc. Oral dosage form of tetrahydrocannabinol and a method of avoiding and/or suppressing hepatic first pass metabolism via targeted chylomicron/lipoprotein delivery
US8980940B2 (en) * 2006-11-10 2015-03-17 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
GB2450753B (en) * 2007-07-06 2012-07-18 Gw Pharma Ltd New Pharmaceutical formulation
US8222292B2 (en) * 2007-08-06 2012-07-17 Insys Therapeutics, Inc. Liquid cannabinoid formulations
CA2698752A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
WO2012071389A2 (en) * 2010-11-22 2012-05-31 Johnson Matthey Public Limited Company Stable cannabinoid compositions and methods for making and storing them
AU2013260246B2 (en) * 2012-05-07 2018-01-25 Echo Pharmaceuticals B.V. Granulate containing cannabinoid, method for its manufacture and oral dosage unit comprising such granulate
EP3007714A1 (en) * 2013-06-13 2016-04-20 Cannabis Science International Holding BV Composition for the treatment of neurobehavioral disorders
MX387604B (es) * 2014-05-29 2025-03-18 Insys Pharma Inc Formulaciones cannabinoides estables.
GB2542155B (en) * 2015-09-09 2018-08-01 Gw Pharma Ltd Use of cannabidiol in the treatment of mental disorders

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021022378A1 (en) * 2019-08-08 2021-02-11 Neptune Wellness Solutions Inc. Oral formulations of cannabis extracts and methods of making same

Also Published As

Publication number Publication date
CN108366988A (zh) 2018-08-03
EP3351242A4 (en) 2019-05-15
BR112018005423B1 (pt) 2020-06-23
US20180264121A1 (en) 2018-09-20
WO2017045053A1 (pt) 2017-03-23
EP3351242A1 (en) 2018-07-25
AU2016322148A1 (en) 2018-04-12
JP2018528985A (ja) 2018-10-04
BR102015024165A2 (pt) 2017-03-28

Similar Documents

Publication Publication Date Title
CA2998739A1 (en) Oral pharmaceutical composition comprising cannabinoid, process for its preparation and use
AU2022201441B2 (en) Stable cannabinoid formulations
Stella et al. Cannabinoid formulations and delivery systems: Current and future options to treat pain
US20250017875A1 (en) Stable cannabinoid formulations
CA3062814C (en) Stable cannabinoid formulations
US20160271252A1 (en) Stable cannabinoid formulations
US20170224634A1 (en) Stable cannabinoid formulations
CA3025702C (en) Stable cannabinoid formulations
US20220054450A1 (en) Stable cannabinoid formulations
WO2022103638A1 (en) Cannabinoids in the treatment of autism spectrum disorder
WO2022027053A1 (en) Micelle preparations of full-spectrum hemp oil for treating type ii diabetes, reducing inflammation during covid-19, and improving sleep quality
JP7627353B2 (ja) チザニジン液体製剤及びその用途
EP3302437B2 (en) Stable cannabinoid formulations
US12011470B2 (en) Micelle preparations of full-spectrum hemp oil
US20220031635A1 (en) Treating COVID 19 by using a mixture of cannabinoids in micellized form to lower levels of pro-inflammatory cytokines and reduce risk of cytokine storm

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210705

EEER Examination request

Effective date: 20210705

EEER Examination request

Effective date: 20210705

EEER Examination request

Effective date: 20210705

FZDE Discontinued

Effective date: 20240109